Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Stock Quote Today & Recent News Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:VM)

Canadian Investment Regulatory Organization Trade Resumption - VM

Canada NewsWire 6 days ago

Voyageur Pharmaceuticals Ltd. Signs Letter of Intent with Global Contrast Imaging Company to Expand Market Reach and Product Portfolio

TheNewsWire 6 days ago

Voyageur Announces Closing of Final Tranche of Private Placement

TheNewsWire 7 days ago

Voyageur Announces Closing of First Tranche of Private Placement

TheNewsWire December 3, 2024

Voyageur Announces Extension to Complete Proposed Private Placement

TheNewsWire November 26, 2024

Voyageur Pharmaceuticals announces $1M raise for contrast drug testing

Coreena Robertson October 29, 2024
View More News ››

Opinion & Analysis (TSXV:VM)

Progress for radiology drugs and medical imaging company

Shoran Devi June 12, 2023

Health Canada Approvals Set Stage for Revenue Generation

Dave Jackson February 25, 2021

From the Earth to the Bottle

Dave Jackson January 21, 2020

VIDEO: High Grade Barite Producer

BTV-Business Television May 18, 2017
View More Opinion ››

Bullboard Posts (TSXV:VM)

RE:C60 must be progressing

according to the VM web site the C60 contrast is 8-10 years for commercialization 
postie1 - 41 minutes ago

RE:GE Healthcare doesn't have any iodine plants in the US.

As a current example, the French contrast media company, Guerbet, has developed a new MRI contrast agent: elucirem-gadopiclenol . This...
lscfa - 6 hours ago

C60 must be progressing

"Launch Fullerene R&D ------------- 200,000" From the Oct.17th news release. If VM is going to start spending money on...
postie1 - 9 hours ago

new product

V-Gas – Voyageur Pharmaceuticals
postie1 - 1 day ago

C60

Their starter molecule C60, is not toxic, that's a huge positive.  The vanadium is trapped inside the molecule and can't...
biggdogg - 1 day ago

RE:GE Healthcare doesn't have any iodine plants in the US.

If you look at iofina, they sell to industrial markets, not Pharmaceuticals. I don't think any US supply is pharma grade. GE tied up...
biggdogg - 1 day ago
View more Bullboard ››

Connect with V.VM

follow v.vm on


PRODUCTS PIPELINE CARBON DRUG PROJECT WHITE PAPER CASE STUDIES MANAGEMENT PRESENTATION

Voyageur Pharmaceuticals Deck 2024

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1